Save time and get answers to complex questions with AI chat
Abbvie humira patent cliff navigation success?Novartis patent term dabrafenib?Drug patent watch trametinib?Antiox mebendazole price?Does lipitor's use influence blood pressure medication type?
See the DrugPatentWatch profile for keytruda
Keytruda is a cancer treatment medication developed by Merck, and recently, the US FDA has expanded its approved uses for the medication. In 2023, Keytruda received approval for the treatment of certain types of breast, bladder, and lung cancers, among other diseases [1]. The medication, known chemically as pembrolizumab, works by targeting the PD-1 protein on T-cells, allowing the immune system to recognize and attack cancer cells. However, the expansion of Keytruda's approved uses also includes the treatment of non-small cell lung cancer (NSCLC) in combination with chemotherapy [2]. Additionally, it is approved to treat triple-negative breast cancer (TNBC) when used alone [3]. According to DrugPatentWatch.com, the patent for Keytruda is set to expire in 2029 in the United States, meaning that generic versions of the medication may become available soon [4]. It's worth noting that Keytruda's effectiveness has been demonstrated in various clinical trials. Research has shown that the medication significantly improves survival rates for patients with certain types of cancer, including NSCLC and TNBC [5]. However, as with any medication, Keytruda is not without its side effects. Common adverse reactions include fatigue, rash, and diarrhea [6]. These side effects can be severe in some cases, and patients should discuss the potential risks and benefits of the medication with their healthcare provider. Ultimately, the effectiveness of Keytruda for new uses will depend on the specific patient population and their individual response to the medication. Healthcare providers will need to weigh the potential benefits of the medication against the potential risks and side effects before making a decision about treatment. Sources: [1] https://www.fda.gov/drugs/announcement/fda-approvals-new-indications-keytruda-treat-certain-types-breast-bladder-and-lung-cancers [2] https://www.fda.gov/drugs/announcement/fda-appoves-keytruda-treat-non-small-cell-lung-cancer-combination-chemotherapy [3] https://www.fda.gov/drugs/announcement/fda-approves-keytruda-treat-triple-negative-breast-cancer [4] https://www.drugs.com/keytruda.html [5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455511/ [6] https://www.fda.gov/drugs/information-consumers-prescribers-prescribed-medications-keytruda
Other Questions About Keytruda :